Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.

Daniel Aaron Pollyea, Courtney Denton Dinardo, Stéphane de Botton, Eytan Stein, et al.

Conclusion: In a high-risk, molecularly defined R/R AML patient population, IVO induced durable remissions and was well tolerated. Studies in previously untreated AML populations are ongoing.

SEE ALSO ARTICLE IN NEJM (Courtney Denton Dinardo, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML)